Skip to main content

Venous Thromboembolism clinical trials at UCSF
3 in progress, 3 open to new patients

  • Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

    open to eligible people ages 18 years and up

    The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant options, and the impact of venous thromboembolism on patient-defined outcomes, such as quality-of-life, symptom burden, and treatment satisfaction. This information is crucial to helping clinicians and patients choose between various treatment options for venous thromboembolism in order to achieve the best possible balance between the risks, benefits, and impact on health.

    Oakland, California and other locations

  • Apixaban for the Acute Treatment of Venous Thromboembolism in Children

    open to eligible people ages up to 17 years

    To assess the safety and extrapolated efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

    Oakland, California and other locations

  • Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

    open to eligible people ages 21 years and up

    The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

    San Francisco, California and other locations